Bastiano Sanna - Apr 4, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Apr 4, 2022
Transactions value $
-$1,021,005
Form type
4
Date filed
4/6/2022, 05:02 PM
Previous filing
Apr 5, 2022
Next filing
Apr 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$81.5K -305 -0.65% $267.10 46.8K Apr 4, 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$69K -257 -0.55% $268.43 46.5K Apr 4, 2022 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$871K -3.16K -6.8% $275.23 43.3K Apr 5, 2022 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $267.10 (range $266.66 to $267.57).
F4 Open market sales reported on this line occurred at a weighted average price of $268.43 (range $267.81 to $268.78).
F5 Open market sales reported on this line occurred at a weighted average price of $275.23 (range $275.00 to $275.66).